

It is possible to design small molecule drugs for a number of diseases (Plenary Session)

Authors: Erika Murray Jennifer Keller Kimberly Gibson Miranda Thornton David Peterson

Published Date: 04-24-2017

California State University-East Bay

School of Chemistry

Presenting the Plenary session of the Pharma Finance Forum, physician Silvia Marti discusses the research conducted by her at Switzerland's University of Applied Sciences Lausanne (URE) on using RNA-RNA chemistry for drug discovery and development.

Silvia Marti is a senior research investigator in the Department of Pharmacology at the University of Applied Sciences Lausanne (URE). Dr. Marti was first assistant in the Department of Genetics at the Lausanne Centre for Genomics, and serves on the scientific and administrative boards of both URE and the Karlsruhe Institute of Technology (KIT) in Germany. From 2000 to 2007, Dr. Marti was deputy head of the Molecular Genetics Group (MGGG) at the JRC (Juhl Institute for Cancer Research) in Copenhagen, Denmark. Currently, she is working on immunogenicity of small molecules as part of the joint research project of the Karlsruhe Institute of Technology (KIT) and the University of Lausanne (URE). Her research is based on the molecular basis of disease and drug interaction, and includes the review of potential targets for new drugs.



A Close Up Of A Black And White Cat